China Resources Pharmaceutical Group Limited (HKG:3320)
5.22
-0.02 (-0.38%)
Mar 28, 2025, 4:08 PM HKT
HKG:3320 Revenue
In the year 2024, China Resources Pharmaceutical Group had annual revenue of 257.67B CNY with 5.30% growth. China Resources Pharmaceutical Group had revenue of 129.08B in the half year ending December 31, 2024, with 20.66% growth.
Revenue
257.67B CNY
Revenue Growth
+5.30%
P/S Ratio
0.12
Revenue / Employee
3.54M CNY
Employees
72,700
Market Cap
32.79B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 257.67B | 12.97B | 5.30% |
Dec 31, 2023 | 244.70B | 26.52B | 12.16% |
Dec 31, 2022 | 218.18B | -18.62B | -7.86% |
Dec 31, 2021 | 236.81B | 36.38B | 18.15% |
Dec 31, 2020 | 200.42B | -4.03B | -1.97% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 19.87B |
JD Health International | 61.89B |
Alibaba Health Information Technology | 31.39B |
Innovent Biologics | 10.03B |
Akeso | 2.01B |
Sino Biopharmaceutical | 30.72B |
China Resources Pharmaceutical Group News
- 6 months ago - Health product chain store CR Care to close all 19 branches in Hong Kong in November - Hong Kong Free Press